Bullish indicating open at $55-$60, IPO prices at $37
Colleen Tupper, the Executive Vice President and Chief Financial Officer of Collegium Pharmaceutical , Inc. (NASDAQ:COLL), recently sold a total of 3,453 shares of the company’s common stock. The transactions, which took place on March 6 and March 7, 2025, were executed under a Rule 10b5-1 trading plan adopted by Tupper in August 2024. According to InvestingPro data, the company maintains a GREAT financial health score, with impressive gross margins of 87% and analyst price targets ranging from $36 to $50.
The shares were sold at prices ranging from $30.00 to $30.0007 per share, culminating in a total sale value of approximately $103,591. Following these transactions, Tupper holds 175,691 shares directly. The stock currently trades at an attractive P/E ratio of 13.9, and InvestingPro analysis suggests the stock is currently undervalued, with 8 additional key insights available to subscribers.
These sales were part of a pre-determined trading plan, which allows company insiders to sell a predetermined number of shares at a predetermined time, helping to avoid any potential accusations of insider trading. Notably, management has been actively buying back shares, demonstrating confidence in the company’s future prospects.
In other recent news, Collegium Pharmaceuticals reported its fourth-quarter 2024 earnings, which exceeded analyst expectations. The company posted an earnings per share (EPS) of $1.75, surpassing the forecast of $1.66, and achieved revenue of $181.9 million against the anticipated $179.48 million. This performance reflects a 22% year-over-year increase in quarterly revenue, driven by strong demand for its ADHD medication, Jornay, and pain management products, BELBUCA and Xtampza ER. Collegium’s annual revenue for 2024 reached $631.4 million, marking an 11% increase from the previous year. Looking ahead, the company projects net product revenue between $735 million and $750 million for 2025, with adjusted EBITDA expected to grow by over 10%. In related developments, the company plans to expand its sales force and invest in digital marketing to boost growth, particularly for its ADHD and pain management portfolios. Additionally, Collegium aims to strategically deploy capital to create shareholder value, as indicated by their recent acquisition of IronSure Therapeutics. These recent developments underscore Collegium’s focus on expanding its market presence and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.